These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1741 related articles for article (PubMed ID: 12771729)
1. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729 [TBL] [Abstract][Full Text] [Related]
2. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin. Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815 [TBL] [Abstract][Full Text] [Related]
3. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
4. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315 [TBL] [Abstract][Full Text] [Related]
5. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. Brake M; Loertzer H; Horsch R; Keller H J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163 [TBL] [Abstract][Full Text] [Related]
6. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936 [TBL] [Abstract][Full Text] [Related]
7. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510 [TBL] [Abstract][Full Text] [Related]
8. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. Zhang GK; Uke ET; Sharer WC; Borkon WD; Bernstein SM J Urol; 1996 Jun; 155(6):1907-9. PubMed ID: 8618284 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T; Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609 [TBL] [Abstract][Full Text] [Related]
11. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin. Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562 [TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457 [TBL] [Abstract][Full Text] [Related]
13. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer. Demkow T; Alter A; Wiechno P Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238 [TBL] [Abstract][Full Text] [Related]
14. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252 [TBL] [Abstract][Full Text] [Related]
20. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer. Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]